Core Viewpoint - The company, DQ Medical-B (06996.HK), announced that its internally developed Claudin 18.2 antibody-drug conjugate (ADC) ATG-022 has received breakthrough therapy designation from the China National Medical Products Administration (NMPA) for the treatment of patients with CLDN18.2 positive, HER2 negative unresectable or metastatic gastric cancer or gastroesophageal junction adenocarcinoma who have previously received at least two treatments [1] Group 1 - The breakthrough therapy designation indicates a significant advancement in the treatment options available for patients with specific types of gastric cancer [1] - ATG-022 targets a specific biomarker (Claudin 18.2), which may enhance treatment efficacy for the identified patient population [1] - The designation by NMPA may expedite the development and review process for ATG-022, potentially leading to earlier market access [1]
德琪医药-B(06996.HK)：ATG-022就治疗胃癌╱胃食管结合部腺癌获授予突破性治疗药物认定